Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment - Experienced, HIV-infected individuals: Recent data and consensus recommendations

HIV Clinical Trials

Volumn 7, Issue 2, 2006, Pages 86-96

  Youle, Mike ^a   Staszweski, Schlomo ^b   Clotet, Bonaventura ^c   Arribas, José Ramon ^d   Blaxhult, Anders ^e   Carosi, Giaampiero ^f   De Jesus, Edwin ^g   Di Perri, Gianni ^h   Estrada, Vicente ⁱ   Fisher, Martin ^j   Kovacs, Colin ^k   Kulasegaram, Ranjababu ^l   Lazzarin, Adriano ^m   Marriot, Debbie ⁿ   Moñoz, Leopoldo ^o   Reynes, Jacques ^p   Shalit, Peter ^q   Slim, Jihad ^r   Tsoukas, Chris ^s   Vaccaro, Anthony ^t   Vera, José ^u   more..

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b GOETHE UNIVERSITY   (Germany)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF BRESCIA   (Italy)

^g ORLANDO IMMUNOLOGY CENTER   (United States)

^h AMEDEO DI SAVOIA HOSPITAL   (Italy)

ⁱ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^j ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^k MAPLE LEAF MEDICAL CLINIC   (Canada)

^l GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^m SAN RAFFAELE HOSPITAL   (Italy)

ⁿ ST VINCENT S HOSPITAL   (Australia)

^o HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^p GUI DE CHAULIAC HOSPITAL   (France)

^q SWEDISH MEDICAL CENTER   (United States)

^r ST MICHAEL S MEDICAL CENTER   (United States)

^s MONTREAL GENERAL HOSPITAL   (Canada)

^t NORTHWESTERN UNIVERSITY   (United States)

^u Centro Hospitalar de Cascais   (Portugal)

more..

Author keywords

Active boosted PI; Enfuvirtide; Triple class experienced

Indexed keywords

ATAZANAVIR; DARUNAVIR; DIDANOSINE; ENFUVIRTIDE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TIPRANAVIR;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CROSS RESISTANCE; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INTERMETHOD COMPARISON; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SUPERINFECTION; TREATMENT DURATION; TREATMENT OUTCOME; VIREMIA; VIRUS INHIBITION; VIRUS LOAD; VIRUS RESISTANCE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PEPTIDE FRAGMENTS; PYRIDINES; PYRONES; RITONAVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33746146917     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/2XVK-PBGL-735N-WH72     Document Type: Article

References (52)

1. Lampe F, Gatell J, Stasewski S, et al. Trends over time in initial virological failure of first HAART, 1996 to 2002: a joint cohort analysis of 4143 subjects [abstract]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; 2005.
2. Bartlett JA, Fath MJ, DeMasi R, et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults [abstract]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; 2005.
3. Clotet B, Raffi F, Cooper D, et al. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS. 2004;18:1137-1146.
4. Pozniak A, Gazzard B, Anderson J, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 2003;4(Suppl 1):1-41.
5. US Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (The living document, October 29, 2004). 2005. Available at: http://aidsinfo.nih.gov/guidelines/adult/AA_100605.pdf.
6. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292:251-265.
7. Robbins GK, De G, V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2293-2303.
8. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2304-2315.
9. Cooper D, Yeni P. Virological and Immunological outcomes at 3 years following initiation of ART with regimens containing a NNRTI or PI or both. The INITIO trial [abstract]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; 2005.
10. MacArthur RD, Chen L, Mayers DL, et al. The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial. Control Clin Trials. 2001;22:176-190.
11. MacArthur RD, Chen L, Peng G, et al. Efficacy and safety of ABC+3TC versus ddl+d4T when combined with a PI, NNRTI or both in AR-naive persons on their first HAART Regimen: the NRTI substudy of the CPCRA 058 FIRST Study [abstract]. Antivir Ther. 2003;8:S333-S334.
12. Lichterfeld M, Wohrmann A, Schmeisser N, et al. Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy. Eur J Med Res. 2003;8:56-60.
13. Eron J, da Silva B, King M, et al. Lopinavir/ritonavir in antiretroviral-naive HIV-infected patients: 5-year follow-up [abstract]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004.
14. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
15. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 2004;189:51-60.
16. MacManus S, Yates PJ, Elston RC, White S, Richards N, Snowden W. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS. 2004;18:651-655.
17. Drusano GL, Bilello JA, Stein DS, et al. Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. J Infect Dis. 1998;178:360-367.
18. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267:483-489.
19. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. 2005. Available at: http://aidsinfo.nih.gov/guidelines. Accessed March 20, 2006.
20. Sabin CA, Hill T, Lampe F, et al. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ. 2005;330:695.
21. Deeks SG, Hellmann NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis. 1999;179:1375-1381.
22. Albrecht MA, Bosch RJ, Hammer SM, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med. 2001;345:398-407.
23. Hammer SM, Vaida F, Bennett KK, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA. 2002;288:169-180.
24. Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis. 2000; 182:1375-1384.
25. Montaner JS, Harrigan PR, Jahnke N, et al. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS. 2001;15:61-69.
26. Montaner JS, Mellors JW. Antiretroviral therapy for previously treated patients. N Engl J Med. 2001;345:452-455.
27. Struble K, Murray J, Cheng B, Gegeny T, Miller V, Gulick R. Antiretroviral therapies for treatment-experienced patients: current status and research challenges. AIDS. 2005; 19:747-756.
28. Food and Drug Administration. Antiviral Drugs Advisory Committee, January 11, 2001. Available at: http://www.fda.gov/oashi/aids/advisorycom.html#2001. Accessed 2005.
29. Sista P, Melby T, Dhingra U, et al. The fusion inhibitors T-20 and T-1249 demonstrate potent in vitro antiviral activity against clade B HIV-1 isolates resistant to reverse transcriptase and protease inhibitors and non-B clades [abstract]. Antivir Ther. 2001;6:3-4.
30. Delfraissy J-F, Montaner J, Eron J, et al. Summary of pooled efficacy and safety analyses of enfuvirtide (ENF) treatment for 24 weeks in TORO 1 and TORO 2 Phase III trials in highly antiretroviral (ARV) treatment-experienced patients [abstract]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; 2003.
31. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr. 2005;40:404-412.
32. Arastéh K, Lazzarin A, Clotet B, et al. TORO: 96 week virological and immunological response and safety evaluation of enfuvirtide with an optimized background regimen [abstract]. Proceedings of the XV International AIDS Conference. 2004;197-201.
33. Youle M, Cohen C, Katlama C, Kuritzkes D, Walmsley S. Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals. Lancet. 2004;364:1036-1037.
34. Miralles GD, DeMasi R. Virologic suppression of an active boosted PI regimen is significantly enhanced by the addition of a fusion inhibitor in treatment-experienced patients [abstract]. In: Program and abstracts of the 42nd Annual Meeting of the Infectious Disease Society of America; 2004.
35. Haubrich R, DeMasi R, Thommes JA. Improved virologic response in three-class experienced patients when an active boosted protease inhibitor is combined with enfuvirtide (ENF) [abstract]. In: Program and abstracts of the 43rd Annual Meeting of IDSA; 2005.
36. Hicks C. RESIST-1: a Phase 3, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24-week data [abstract]. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004.
37. Cahn P. 24-week data from RESIST 2: Phase 3 study of the efficacy and safety of either tipranavir/ritonavir (TPV/r) or an optimized ritonavir (RTV)-boosted standard-of-care (SOC) comparator PI (CPI) in a large randomized multicenter trial in treatment-experienced HIV+ patients [abstract]. In: Program and abstracts of the 7th International Congress on Drug Therapy in HIV Infection; 2004.
38. Cooper D, Hicks C, Cahn P, et al. 24-week RESIST Study analyses: the efficacy of tipranavir/ritonavir (TPV/r) is superior to lopinavir/ ritonavir (LPV/r), and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen (OBR) [abstract]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; 2005.
39. Cahn P, Hicks C. RESIST-1 (R-1) and RESIST-2 (R-2) 48-week meta-analysis demostrate superiority of protease inhibitor (PI) tipranavir+ritonavir (TPV/r) over an optimised comparator PI (CPI/r) regimen in antiretroviral (ARV) experienced patients. In: Program and abstracts of the 10th European AIDS Conference; Dublin, Ireland. Abstract LBPS3/8.
40. Schapiro J, Cahn P, Trottier B, et al. Effect of baseline genotype on response to tipranavir/ritonavir compared with standard-of-care comparator in treatment-experienced patients: The Phase 3 RESIST-1 and -2 Trials [abstract]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; 2005.
41. Boehringer Ingelheim Pharmaceuticals I. Tipranavir: Antiviral Drugs Advisory Committee Briefing Document. 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/ 2005-4139b1-02-boehringer.pdf
42. Hill A, Moyle G. Relative antiviral efficacy of TMC114/r and tipranavir/ r versus control PI in the POWER and RESIST trials [abstract]. In: Program and abstracts of the 12th Annual Conference of the British HIV Association (BHIVA); 2006.
43. D'Aquila R, Schapiro J, Brun-Vézinet F, et al. Drug resistance mutations in HIV-1. Top HIV Med. 2003;11:92-96.
44. Katlama C, Berger D, Bellos N, et al. Efficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials [abstract]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; 2005.
45. Katlama C, Carvalho M, Cooper D, et al. POWER: TMC114-C213 study - week 24 analysis [abstract]. In: Program and abstracts of the 3rd International AIDS Society Conference; 2005.
46. Wilkin T, Haubrich R, Steinhart C, et al. POWER 2 (TMC114-C202) week 24 efficacy analysis. Poster presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); December 16-19, 2005; Washington, DC, USA. Poster 2860.
47. Berger D, Bellos N, Farthing C, et al. TMC114/r in 3-class-experienced patients: 24-week primary safety analysis of the POWER 2 study (TMC114-C202). In: Poster presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); December 16-19, 2005; Washington, DC, USA. Poster H-1094.
48. Montaner J, Guimaraes D, Chung J, Gafoor Z, Salgo M, DeMasi R. Prognostic staging of extensively pretreated patients with advanced HIV-1 disease. HIV Clin Trials. 2005;6:281-290.
49. Martin D, Jacobson J, Schurmann D, et al. PA-457, the first-in-class maturation inhibitor, exhibits antiviral activity following a single oral dose in HIV-1-infected patients [abstract]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; 2005.
50. Little S, Drusano G, Schooley R, et al. Antiretroviral effect of L-000870810, a novel HIV-1 integrase inhibitor, in HIV-1-infected patients [abstract]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; 2005.
51. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002;46:1896-1905.
52. Menzo S, Castagna A, Monachetti A, et al. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother. 2004;48:3253-3259.